LimmaTech

“It will pay up to $780 million for LimmaTech, a Swiss firm focused on bacterial pathogens like Staphylococcus aureus. It had raised $40m from firms like Tenmile, Repair Impact Fund, AXA Investment Managers, Novo Holdings, Adjuvant Capital and CARB-X.”